Modulators of TNF-alfa signaling
AssigneeGenzyme Corporation
InventorsScott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas: 1
Claims59
A compound of Formula I,
- 388
- or a physiologically acceptable salt thereof, wherein:
- n is 0, 1 or 2;
- X is O, CH2, S or SO2;
- R1 is H or NH2;
- R2 and R3 are each, independently, —H, —OH, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkoxy;
- R4 is, —H or a substituted or unsubstituted alkyl;
- V, W and Z are each, independently, N or CH;
- and
- Y is selected from the group consisting of substituted and unsubstituted phenyl, substituted and unsubstituted heterocyclyl.
A compound represented by the following structural formula:
- 389
- or a physiologically acceptable salt thereof.
A compound represented by the following structural formula:
- 390
- or a physiologically acceptable salt thereof.
A compound of Formula II,
- 391
- or a physiologically acceptable salt thereof, wherein,
- R5 is substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted cycloalkylalkyl;
- R6 is —H or —NR13R14;
- R7 is substituted or unsubstituted phenyl;
- and
- R13 and R14 are each, independently, —H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl;
- or
- R13 and R14 together with the nitrogen to which they are attached are a heterocycloalkyl.
A method of treating a TNF-α mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula I,
- 392
- or a physiologically acceptable salt thereof, wherein:
- n is 0, 1 or 2;
- X is O, CH2, S or SO2;
- R1, is H or NH2;
- R2 and R3 are each, independently, —H, —OH, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkoxy;
- R4 is, —H or a substituted or unsubstituted alkyl;
- V, W and Z are each, independently, N or CH;
- and
- Y is selected from the group consisting of substituted and unsubstituted phenyl, and substituted and unsubstituted heterocyclyl.
A method of treating a TNF-α mediated condition in a patient, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:
- 393
- or a physiologically acceptable salt thereof.
A method of treating a TNF-α mediated condition in a patient, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:
- 394
- or a physiologically acceptable salt thereof.
A method of treating a TNF-α mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula II,
- 395
- or a physiologically acceptable salt thereof, wherein,
- R5 is substituted or unsubstituted aralkyl, susbstituted or unsubstituted cycloalkyl, or substituted or unsubstituted cycloalkylalkyl;
- R6 is —H or —NR13R14;
- R7 is substituted or unsubstituted phenyl;
- and
- R13 and R14 are each, independently, —H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl;
- or
- R13 and R14 together with the nitrogen to which they are attached are a heterocycloalkyl.
A method of treating multiple sclerosis in a patient, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:
- 396
- or a physiologically acceptable salt thereof.
A compound of Formula I,
- 397
- or a physiologically acceptable salt thereof, wherein:
- n is 0, 1 or 2;
- X is O, CH2, S or SO2;
- R1 is H or NH2;
- R2 and R3 are each, independently, —H, —OH, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkoxy;
- R4 is, —H or a substituted or unsubstituted alkyl;
- V, W and Z are each, independently, N or CH;
- and
- Y is represented by the following structural formula:
- 398
- wherein R50 and R51 are independently an alkyl group, a substituted alkyl group, an aryl group a substituted aryl group, or, taken together with the nitrogen atom to which they are bonded, are a substituted heterocycloalkyl, an unsubstituted heterocycloalkyl, a substituted heteroaryl group or an unsubstituted heteroaryl group.
A compound represented by the following structural formula:
- 399
- or a physiologically acceptable salts thereof.
A compound represented by the following structural formula:
- 400
- or a physiologically acceptable salts thereof.
Dependencies are inferred from the claim text.